The creation of retatrutide, a novel dual agonist targeting both GLP-1 and GIP receptors, represents a complex complicated chemical process. Early routes focused on peptide section coupling, utilizing solid-phase synthesis methodologies to build the long peptide sequence. Subsequent investigation has explored alternative approaches, including enzym